Evidence map›Paper›PMID 27031621›Full record

ArticlePLoS neglected tropical diseases2016

Rift Valley Fever Vaccine Virus Clone 13 Is Able to Cross the Ovine Placental Barrier Associated with Foetal Infections, Malformations, and Stillbirths.

Birgit Makoschey, Emma van Kilsdonk, Willem R Hubers, Mieke P Vrijenhoek, Marianne Smit, Paul J Wichgers Schreur, Jeroen Kortekaas, Véronique Moulin

Open access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 75 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. The public health threat of emerging phenuiviruses.One health (Amsterdam, Netherlands) · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Birgit MakoscheyIntervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands.
Emma van KilsdonkIntervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands.
Willem R HubersIntervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands.
Mieke P VrijenhoekIntervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands.
Marianne SmitIntervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands.
Paul J Wichgers SchreurDepartment of Virology, Central Veterinary Institute, Wageningen University and Research Centre, Lelystad, The Netherlands.
Jeroen KortekaasDepartment of Virology, Central Veterinary Institute, Wageningen University and Research Centre, Lelystad, The Netherlands.
Véronique MoulinIntervet International BV/Merck Sharp and Dohme (MSD) Animal Health, Boxmeer, The Netherlands.
MSD (Netherlands) · NLWageningen University & Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rift Valley fever virus (RVFV) is a mosquito-borne pathogen that affects domesticated ruminants and occasionally humans. Classical RVF vaccines are based on formalin-inactivated virus or the live-attenuated Smithburn strain. The inactivated vaccine is highly safe but requires multiple administrations and yearly re-vaccinations. Although the Smithburn vaccine provides solid protection after a single vaccination, this vaccine is not safe for pregnant animals. An alternative live-attenuated vaccine, named Clone 13, carries a large natural deletion in the NSs gene which encodes the major virulence factor of the virus. The Clone 13 vaccine was previously shown to be safe for young lambs and calves. Moreover, a study in pregnant ewes suggested that the vaccine could also be applied safely during gestation. To anticipate on a possible future incursion of RVFV in Europe, we have evaluated the safety of Clone 13 for young lambs and pregnant ewes. In line with the guidelines from the World Organisation for Animal health (Office International des Epizooties, OIE) and regulations of the European Pharmacopeia (EP), these studies were performed with an overdose. Our studies with lambs showed that Clone 13 dissemination within vaccinated animals is very limited. Moreover, the Clone 13 vaccine virus was not shed nor spread to in-contact sentinels and did not revert to virulence upon animal-to-animal passage. Importantly, a large experiment with pregnant ewes demonstrated that the Clone 13 virus is able to spread to the fetus, resulting in malformations and stillbirths. Altogether, our results suggest that Clone 13 can be applied safely in lambs, but that caution should be taken when Clone 13 is used in pregnant animals, particularly during the first trimester of gestation.

Indexed as

AnimalsAntibodies, ViralCongenital AbnormalitiesDose-Response Relationship, ImmunologicFemaleInfectious Disease Transmission, VerticalPlacentaPregnancyPregnancy Complications, InfectiousRift Valley FeverRift Valley fever virusSheepSheep DiseasesStillbirthViral VaccinesVirulenceAntibodies, ViralViral Vaccines

Identifiers

PMID27031621
PMCPMC4816553
OpenAlexW2326590554

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.